Analysed XTL BIOPHARMACEUTICALS-ADR (XTLB:NASDAQ) News Sources
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
24-12-2025
yahoo.com
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
13-01-2026
yahoo.com
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
13-01-2026
yahoo.com
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency
23-01-2026
yahoo.com
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
27-02-2026
yahoo.com
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
29-04-2026
yahoo.com
What is the current price of XTL BIOPHARMACEUTICALS-ADR (XTLB:NASDAQ)?
The current price of XTL BIOPHARMACEUTICALS-ADR (XTLB:NASDAQ) is $2.29.
XTL BIOPHARMACEUTICALS-ADR (XTLB:NASDAQ) absolute price change since previous trading day?
The absolute price change of XTL BIOPHARMACEUTICALS-ADR (XTLB:NASDAQ) since the previous trading day is $-0.11.
XTL BIOPHARMACEUTICALS-ADR (XTLB:NASDAQ) percentage price change since previous trading day?
The percentage price change of XTL BIOPHARMACEUTICALS-ADR (XTLB:NASDAQ) since the previous trading day is -4.5833%.
What is the most recent average sentiment score for XTL BIOPHARMACEUTICALS-ADR (XTLB:NASDAQ)?
The most recent average sentiment score for XTL BIOPHARMACEUTICALS-ADR (XTLB:NASDAQ) is 69 out of 100.
What is the most recent average sentiment for XTL BIOPHARMACEUTICALS-ADR (XTLB:NASDAQ)?
The most recent sentiment for XTL BIOPHARMACEUTICALS-ADR (XTLB:NASDAQ) is .
SEC-8K** Filing Available For XTL BIOPHARMACEUTICALS-ADR (XTLB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.